

References

L-102

1. Ward M, Hackenmueller S, Strathmann F, et al. Pathology consultation on urine compliance testing and drug abuse screening. *American Journal of Clinical Pathology*. 2014;142(5):586-93.
2. Nuckols T, Anderson L, Popescu I, et al. Opioid prescribing: A systematic review and critical appraisal of guidelines for chronic pain. *Annals of Internal Medicine*. 2014;160(1):38-47.
3. Dupouy J, Memier V, Catala H, et al. Does urine drug abuse screening help for managing patients? A systematic review. *Drug Alcohol Depend*. 2014;136:11-20.
4. Conermann T, Gosalia A, Kabazie A, et al. Utility of oral fluid in compliance monitoring of opioid medications. *Pain Physician*. 2014;17(1):63-70.
5. American Pain Society (APS)/ American Academy of Pain Medicine (AAPM). Clinical guidelines for chronic opioid therapy in patients with noncancer pain. 2013.
6. Davis K, Sadler A, Genzen J. A retrospective analysis of urine drugs of abuse immunoassay true positive rates at a national reference laboratory. *Journal of Analytical Toxicology*. 2016;40(2):97-107.
7. Krishnamurthy P, Ranganathan G, Williams C, et al. Impact of urine drug screening on no shows and dropouts among chronic pain patients: A propensity-matched cohort study. *Pain Physician*. 2016;19(2):89-100.
8. Dowell D, Haegerich TM, Chou R. Centers for Disease Control and Prevention (CDC) guideline for prescribing opioids for chronic pain-United States. *Journal of the American Medical Association*. 2016;315(15):1624-1645.
9. Washington State Agency Medical Directors' Group. Interagency guideline on prescribing opioid dosing for pain. 2015.
10. 42 CFR 8.12 - Federal opioid treatment standards. April 2017.
11. Substance Abuse and Mental Health Services Administration (SAMHSA). Medication and counseling treatment. 2015.
12. United States Department of Labor. Mental health and substance use disorder parity. The Mental Health Parity and Addiction Equity Act of 2008 (MHPAEA).
13. Pennsylvania Act 106, (of 1989), 40 P.S. §§ 908-1 – 908-8. Pennsylvania benefit plans, drug and alcohol use and dependency coverage; Notice 2003-06. Pa.B. Doc. No. 03-1566. August 2003.
14. Snyder ML, Fantz CR, Melanson S. Immunoassay-based drug tests are inadequately sensitive for medication compliance monitoring in patients treated for chronic pain. *Pain Physician*. Feb 2017;20(2S):SE1-SE9.
15. Bertholf RL, Sharma R, Reisfield GM. Predictive value of positive drug screening results in an urban outpatient population. *J Anal Toxicol*. Nov 2016;40(9):726-731.
16. Brennan PL, Del Re AC, Henderson PT, et al. Healthcare system-wide implementation of opioid-safety guideline recommendations: the case of urine drug screening and opioid-patient suicide- and overdose-related events in the Veterans Health Administration. *Transl Behav Med*. Dec 2016;6(4):605-612.